Background
CROMSOURCE was engaged by a mid-size US biotech company to provide biostatistical consultancy services for their pivotal phase III study. The trial involved a highly advanced and very specific stem cell therapy for the treatment of metastatic melanoma and was highly anticipated by the medical community. The client had been working on the protocol design for more than a year but was unable to start the study without securing additional funding to cover the cost of the project.
DownloadFile | Action |
---|---|
CROMSOURCE Case Study - Biometrics - Streamline Cost, Adjusting Protocol.pdf | Download |